Topics

AZN's POSEIDON Has Poise, MRTX On The Move, MOR Drops Atopic Dermatitis Trial

03:54 EDT 29 Oct 2019 | RTTNews

Today's Daily Dose brings you news about Mirati's phase I/II trial results of MRTX849 in patients with solid tumors; MorphoSys' decision to discontinue the clinical development program of MOR106 in atopic dermatitis. Medpace's Q3 results; Orthofix Medical trimming its 2019 outlook and AstraZeneca's POSEIDON trial results, to name a few.

Original Article: AZN's POSEIDON Has Poise, MRTX On The Move, MOR Drops Atopic Dermatitis Trial

NEXT ARTICLE

More From BioPortfolio on "AZN's POSEIDON Has Poise, MRTX On The Move, MOR Drops Atopic Dermatitis Trial"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Eczema
Eczema is a common itchy skin disease characterized by reddening and vesicle formation, which may lead to weeping and crusting. It is endogenous, or constitutional. There are five main types; atopic, seborrhoeic, discoid, gravitational or varicose. ...

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...